Insights on increasing the translational value of your preclinical development program.
Aug 11, 2026by MD Biosciences
Osteoarthritis is one of the largest unmet needs in pain, and one of the most stubborn translational problems in the...
Aug 4, 2026by MD Biosciences
Most preclinical neuroscience programs are still built around two categories of evidence. Behavior tells you what the...
Jul 28, 2026by MD Biosciences
Histology has always carried a quiet tension. It is the most direct evidence a preclinical study can offer, a look at...
Jul 21, 2026by MD Biosciences
Remyelination has become the most interesting frontier in multiple sclerosis. The approved therapies for relapsing...
Jul 14, 2026by MD Biosciences
AAALAC accreditation carries practical weight in preclinical drug development, and its implications for program quality...
.png?width=1330&height=748&name=Webinar%20Socials%20(8).png)
.png?width=1332&height=748&name=Webinar%20Socials%20(5).png)
.png?width=800&height=924&name=POP%20in%20pigs%20webinar%20(1).png)
